# HCW Biologics Inc.: Form 10-K for the period ended Dec 31, 2025

- Company: [HCW Biologics Inc.](/companies/hcwb.md) (CIK 1828673)
- Form: 10-K
- Filed: 2026-03-31
- Accepted by EDGAR: Mar 31, 2026, 17:12 ET
- Period: 2025-12-31
- Accession: 0001193125-26-134934
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/hcwb-20251231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2025-01-01 to 2025-12-31 | $54.2k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 12 months, 2025-01-01 to 2025-12-31 | $43.4k | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2025-01-01 to 2025-12-31 | $10.8k | us-gaap:GrossProfit |
| Research and development | 12 months, 2025-01-01 to 2025-12-31 | $5.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2025-01-01 to 2025-12-31 | −$13.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2025-01-01 to 2025-12-31 | $845.1k | us-gaap:InterestExpense |
| Income tax | 12 months, 2025-01-01 to 2025-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2025-01-01 to 2025-12-31 | −$8.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2025-01-01 to 2025-12-31 | −$10.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2025-01-01 to 2025-12-31 | −$10.63 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2025-01-01 to 2025-12-31 | 2,097,701 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | −$13.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2025-01-01 to 2025-12-31 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-12-31 | $2.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-12-31 | $2.3m | us-gaap:AssetsCurrent |
| Total assets | at 2025-12-31 | $24.5m | us-gaap:Assets |
| Current liabilities | at 2025-12-31 | $21.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-12-31 | $21.8m | us-gaap:Liabilities |
| Long-term debt | at 2025-12-31 | $0 | us-gaap:LongTermDebt |
| Short-term borrowings | at 2025-12-31 | $6.8m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2025-12-31 | $2.8m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/hcwb-20251231.htm

Filed Mar 31, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-134934. Last ingested by Listed: Nov 5, 2026, 12:33 ET. No prices; not investment advice.
